PCPI® is a membership organization uniquely focused on improving health outcomes through the advancement of performance measurement, clinical registries and quality improvement initiatives. Since 2000, PCPI has been a leader in convening experts to develop performance measures that improve the quality of healthcare for stakeholders across all of healthcare. We have a proven commitment to quality and have developed over 300 performance measures, 90 endorsed by NQF.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy

KITE AND SHORELINE BIOSCIENCES FORM STRATEGIC PARTNERSHIP TO DEVELOP NOVEL ALLOGENEIC CELL THERAPIES

Kite, Shoreline Biosciences | June 18, 2021

news image

Kite, a Gilead Company, and Shoreline Biosciences, Inc., a biotechnology firm developing intelligently designed allogeneic off-the-shelf, standardized, and targeted natural killer (NK) and Macrophage cellular immunotherapies achieved from induced pluripotent stem cells (iPSC) for cancer and other serious diseases, announced a strategic partnership today to develop novel cell therapies across a variety of indications. The collaboration will combine Shoreline’s profound experi...

Read More

Industrial Impact

AGILENT ATTAINS ‘ANGEL’ LEVEL SPONSORSHIP WITH MY GREEN LAB

Agilent Technologies | December 01, 2022

news image

cevel sponsor of My Green Lab, a nonprofit organization dedicated to building a global culture of sustainability in science. ‘Angel’ level sponsorship provides Agilent access to even more strategic counsel from My Green Lab in support of its sustainability activities and expertise that can be shared with customers. Agilent is also the proud sponsor of the My Green Lab Certification program – considered the gold standard for laboratory sustainabilit...

Read More

AEGLE THERAPEUTICS RECEIVES RARE PEDIATRIC DISEASE DESIGNATION FROM THE FDA FOR AGLE-102 FOR PATIENTS WITH DYSTROPHIC EPIDERMOLYSIS BULLOSA

Aegle Therapeutics | October 06, 2020

news image

Aegle Therapeutics Corporation, a first-in-class biotechnology company committed to delivering cell-free therapy to patients affected by severe dermatological conditions, today announced that the FDA has granted Rare Pediatric Disease (RPD) Designation to AGLE-102™ for the treatment of dystrophic epidermolysis bullosa (DEB), a skin blistering disorder. AGLE-102 is a composite of mesenchymal stem cell-derived extracellular vesicles that deliver proteins, genetic material and regenerat...

Read More

Industrial Impact

LEICA BIOSYSTEMS AND LEAP THERAPEUTICS PARTNER ON COMPANION DIAGNOSTIC TO ADVANCE CARE FOR CANCER PATIENTS

Leap Therapeutics, Inc. | February 01, 2022

news image

Leica Biosystems, a cancer diagnostics company, has entered into an agreement with Leap Therapeutics, a biotechnology company, to develop a companion diagnostic to detect Dickkopf-related protein 1. The assay will be used to support clinical development of Leap Therapeutics' anti-DKK1 cancer therapy, DKN-01, currently being studied in clinical trials. DKK1 is a protein often implicated in cancer, enabling tumor cells to suppress the immune system and lead to unregulated growth...

Read More
news image

Cell and Gene Therapy

KITE AND SHORELINE BIOSCIENCES FORM STRATEGIC PARTNERSHIP TO DEVELOP NOVEL ALLOGENEIC CELL THERAPIES

Kite, Shoreline Biosciences | June 18, 2021

Kite, a Gilead Company, and Shoreline Biosciences, Inc., a biotechnology firm developing intelligently designed allogeneic off-the-shelf, standardized, and targeted natural killer (NK) and Macrophage cellular immunotherapies achieved from induced pluripotent stem cells (iPSC) for cancer and other serious diseases, announced a strategic partnership today to develop novel cell therapies across a variety of indications. The collaboration will combine Shoreline’s profound experi...

Read More
news image

Industrial Impact

AGILENT ATTAINS ‘ANGEL’ LEVEL SPONSORSHIP WITH MY GREEN LAB

Agilent Technologies | December 01, 2022

cevel sponsor of My Green Lab, a nonprofit organization dedicated to building a global culture of sustainability in science. ‘Angel’ level sponsorship provides Agilent access to even more strategic counsel from My Green Lab in support of its sustainability activities and expertise that can be shared with customers. Agilent is also the proud sponsor of the My Green Lab Certification program – considered the gold standard for laboratory sustainabilit...

Read More
news image

AEGLE THERAPEUTICS RECEIVES RARE PEDIATRIC DISEASE DESIGNATION FROM THE FDA FOR AGLE-102 FOR PATIENTS WITH DYSTROPHIC EPIDERMOLYSIS BULLOSA

Aegle Therapeutics | October 06, 2020

Aegle Therapeutics Corporation, a first-in-class biotechnology company committed to delivering cell-free therapy to patients affected by severe dermatological conditions, today announced that the FDA has granted Rare Pediatric Disease (RPD) Designation to AGLE-102™ for the treatment of dystrophic epidermolysis bullosa (DEB), a skin blistering disorder. AGLE-102 is a composite of mesenchymal stem cell-derived extracellular vesicles that deliver proteins, genetic material and regenerat...

Read More
news image

Industrial Impact

LEICA BIOSYSTEMS AND LEAP THERAPEUTICS PARTNER ON COMPANION DIAGNOSTIC TO ADVANCE CARE FOR CANCER PATIENTS

Leap Therapeutics, Inc. | February 01, 2022

Leica Biosystems, a cancer diagnostics company, has entered into an agreement with Leap Therapeutics, a biotechnology company, to develop a companion diagnostic to detect Dickkopf-related protein 1. The assay will be used to support clinical development of Leap Therapeutics' anti-DKK1 cancer therapy, DKN-01, currently being studied in clinical trials. DKK1 is a protein often implicated in cancer, enabling tumor cells to suppress the immune system and lead to unregulated growth...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us